Natural AR ligands showed limited effects in treating ER + BC in trials dating back to the 1950s [12, 13], while a trial of AR antagonist in combination with an aromatase inhibitor showed improved prognosis in a subpopulation of BC patients with high AR and low ERα levels [14]. Here, CYP19A1 is linked to breast cancer.